14-day Premium Trial Subscription Sign Up For FreeGet Free

ChemoCentryx Stock Forecast NASDAQ:CCXI

$36.15 (3.20%)

Volume: 1M

Closed: Dec 07, 2021

Hollow Logo Score: -3.824

ChemoCentryx Stock Forecast

$36.15 (3.20%)

Volume: 1M

Closed: Dec 07, 2021

Score Hollow Logo -3.824

ChemoCentryx Stock Forecast NASDAQ:CCXI

Price Target and Analyst Ratings

Most Recent Rating

On Nov 10, 2021 "Raymond James" gave "$107.00 - $110.00" rating for CCXI. The price target was set to $38.86+2.2%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-11-10 $107.00 - $110.00 Target Raised by Raymond James $37.99 $38.86+2.2%
2021-11-09 Reiterated by SVB Leerink $38.02 $38.51→2.2%
2021-10-11 $14.00 - $38.00 Upgraded by JPMorgan Chase & Co. $40.50 $38.64+0.6%
2021-10-11 $64.00 Upgraded by SVB Leerink $40.50 $38.41+96.0%
2021-10-08 Upgraded by Piper Sandler $38.41 $36.11+84.2%
2021-10-08 $62.00 - $107.00 Upgraded by Raymond James $38.41 $36.11+84.2%
2021-10-08 $31.00 - $85.00 Target Raised by Stifel Nicolaus $38.41 $37.86+93.2%
2021-10-08 $28.00 - $101.00 Target Raised by HC Wainwright $38.41 $38.41+96.0%
2021-08-11 $79.00 - $64.00 Target Lowered by Canaccord Genuity $14.41 $14.31→2.0%
2021-07-07 Buy Reiterated by Canaccord Genuity $14.47 $79.00
2021-07-06 Hold - Buy Upgraded by Stifel Nicolaus $14.05
2021-05-13 Outperform - Market Perform Reiterated by SVB Leerink $9.97 $84.00 → $17.00
2021-05-13 Buy - Hold Reiterated by Stifel Nicolaus $9.97 $93.00 → $26.00
2021-05-13 Neutral - Underweight Reiterated by JPMorgan Chase & Co. $9.97 $57.00 → $17.00
2021-05-13 Strong-Buy - Outperform Reiterated by Raymond James $9.97 $120.00 → $51.00
2021-05-13 Buy Target Lowered by HC Wainwright $9.97 $101.00 → $28.00
2021-05-12 Overweight - Neutral Reiterated by Piper Sandler $10.05 $80.00 → $25.00
2021-05-07 Buy Target Lowered by HC Wainwright $10.46 $101.00 → $28.00
2021-05-07 Buy - Hold Downgraded by Stifel Nicolaus $10.46
2021-05-07 Neutral - Underweight Downgraded by JPMorgan Chase & Co. $10.46 $57.00 → $17.00
2021-05-07 Outperform - Market Perform Downgraded by SVB Leerink $10.46
2021-05-07 Strong-Buy - Outperform Downgraded by Raymond James $10.46 $120.00 → $51.00
2021-05-06 Overweight - Neutral Downgraded by Piper Sandler $27.49
2021-05-05 Buy Reiterated by Canaccord Genuity $27.49
2021-03-08 Buy Initiated by Stifel Nicolaus $55.29 $93.00
2021-03-08 Strong-Buy Target Raised by Raymond James $55.29 $119.00 → $120.00
2021-03-02 Buy Target Raised by HC Wainwright $66.80 $83.00 → $101.00
2021-03-02 Strong-Buy Target Raised by Raymond James $66.80 $119.00 → $120.00
2021-03-01 Buy Initiated by Stifel Nicolaus $68.40
2021-01-08 Strong-Buy Target Raised by Raymond James $62.78 $100.00 → $119.00
2020-10-29 Overweight - Neutral Downgraded by JPMorgan Chase & Co. $49.52 $63.00 → $60.00
2020-10-29 Overweight Target Raised by Piper Sandler $49.52 $67.00 → $71.00
2020-10-29 Outperform Target Raised by SVB Leerink $49.52 $75.00 → $84.00
2020-10-29 Overweight Target Lowered by Wells Fargo & Company $49.52 $79.00 → $70.00
2020-09-17 Target Raised by HC Wainwright $52.57 $73.00 → $85.00
2020-08-12 Outperform Target Raised by SVB Leerink $52.99 $65.00 → $75.00
2020-08-12 Outperform Target Raised by SVB Leerink $52.99 $65.00 → $75.00
2020-08-11 Strong-Buy Target Raised by Raymond James $53.66 $95.00 → $100.00
2020-07-29 Overweight Target Lowered by JPMorgan Chase & Co. $52.65 $64.00 → $61.00
2020-06-16 Buy Initiated by BTIG Research $62.16 $70.00
2020-06-03 Buy Reiterated by Canaccord Genuity $60.58
2020-05-27 Overweight Initiated by Wells Fargo & Co $63.14 $79.00
2020-05-19 Buy Target Lowered by Canaccord Genuity $56.02 $68.00 → $58.00
2020-05-18 Reduce - Overweight Target Raised by Piper Sandler $58.49 $54.00 → $70.00
2020-05-14 Overweight Target Raised by JPMorgan Chase & Co. $52.22 $61.00 → $64.00
2020-05-12 Buy Target Raised by Canaccord Genuity $56.52 $64.00 → $68.00
2020-05-12 Buy Target Raised by HC Wainwright $56.52 $60.00 → $69.00
2020-05-12 Strong-Buy Target Raised by Raymond James $56.52 $38.00 → $102.00
2020-05-12 Outperform Target Raised by SVB Leerink $56.52 $54.00 → $65.00

CCXI Stock Trend

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $35.46 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift.

Given the current short-term trend, the stock is expected to rise 89.24% during the next 3 months and, with a 90% probability hold a price between $67.11 and $109.40 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-12-09 $35.90 $47.07 $58.24
2021-12-10 $36.33 $47.50 $58.67
2021-12-13 $36.76 $47.93 $59.11
2021-12-14 $37.19 $48.37 $59.54
2021-12-15 $37.63 $48.80 $59.97
2021-12-16 $38.06 $49.23 $60.40
2021-12-17 $38.49 $49.66 $60.84
2021-12-20 $38.92 $50.10 $61.27
2021-12-21 $39.36 $50.53 $61.70
2021-12-22 $39.79 $50.96 $62.14
2021-12-23 $40.22 $51.40 $62.57
2021-12-27 $40.66 $51.83 $63.00
2021-12-28 $41.09 $52.26 $63.43
2021-12-29 $41.52 $52.69 $63.87
2021-12-30 $41.95 $53.13 $64.30
2021-12-31 $42.39 $53.56 $64.73
2022-01-03 $42.82 $53.99 $65.16
2022-01-04 $43.25 $54.42 $65.60
2022-01-05 $43.68 $54.86 $66.03
2022-01-06 $44.12 $55.29 $66.46
2022-01-07 $44.55 $55.72 $66.90
2022-01-10 $44.98 $56.16 $67.33
2022-01-11 $45.41 $56.59 $67.76
2022-01-12 $45.85 $57.02 $68.19
2022-01-13 $46.28 $57.45 $68.63
2022-01-14 $46.71 $57.89 $69.06
2022-01-17 $47.15 $58.32 $69.49
2022-01-18 $47.58 $58.75 $69.92
2022-01-19 $48.01 $59.18 $70.36
2022-01-20 $48.44 $59.62 $70.79

About ChemoCentryx

ChemoCentryx ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the United States. Its lead drug candidates in clinical development include CCX168, which is in Phase II clinical trials for the treatment of orphan and rare diseases; CCX872, which is in Phase I... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT